Standout Papers

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potenti... 1996 2026 2006 2016 703
  1. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators (1996)
    Tetsuhiko Shirasaka, Hideyuki Ohshimo et al. Anti-Cancer Drugs

Immediate Impact

2 from Science/Nature 63 standout
Sub-graph 1 of 21

Citing Papers

Pancreatic cancer
2025 Standout
Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout
13 intermediate papers

Works of Hideyuki Ohshimo being referenced

A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA
2004
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA
2004
and 5 more

Author Peers

Author Last Decade Papers Cites
Hideyuki Ohshimo 993 704 280 315 17 1.4k
Kazuhiko Yonekura 761 617 468 291 23 1.3k
Yasushi Mitachi 721 704 121 292 18 1.0k
N. Schleucher 789 601 591 353 32 1.6k
Alice Chen 1280 603 152 234 14 1.7k
Ірина Давиденко 797 576 392 280 31 1.6k
P. Fidias 855 947 301 165 39 1.2k
Marie‐Pierre Galais 766 649 234 422 38 1.3k
M Nishida 1190 372 186 242 14 1.4k
M. E. Vega-Villegas 931 542 146 269 17 1.2k
Hao Yu 755 556 262 160 26 1.1k

All Works

Loading papers...

Rankless by CCL
2026